Shorter alcohol medication trials may match longer studies
A meta-analysis found trials of 12 weeks or less can assess alcohol use disorder drugs as well as longer studies.
By Priya Raghavan · Science Reporter
3 min read
Clinical trials for alcohol use disorder medications may not need to run for six months to produce useful evidence, according to a meta-analysis published in Alcohol: Clinical and Experimental Research. The finding matters because shorter studies could reduce costs, limit the burden on participants and speed access to other treatments for people who are not helped by an experimental drug.
The analysis found that randomized controlled trials lasting less than 12 weeks produced results similar to longer trials when researchers assessed whether medications helped people reduce or stop drinking. Among studies where a medication showed a statistically significant benefit, trials of 12 weeks or less produced more reliable results than longer ones, according to the authors.
The finding runs against current U.S. Food and Drug Administration guidance, which recommends that clinical trials of medications for alcohol use disorder last at least six months. The authors said regulators and researchers should consider whether shorter study designs can answer key questions while lowering risks and burdens for participants.
What the researchers reviewed
The researchers used a meta-regression to examine 139 randomized controlled trials conducted from 1985 through 2023. Those studies tested 19 pharmacotherapies for alcohol use disorder.
The team compared effect sizes, meaning the difference in outcomes between participants receiving a medication and those receiving a placebo. They looked at trials lasting 12 weeks, trials shorter than 12 weeks and trials longer than 12 weeks.
The authors assessed outcomes tied to abstinence and reduced drinking. In 12-week trials, medications performed significantly better than placebo on both measures, according to the analysis. The pattern was consistent when the researchers looked at trials shorter and longer than 12 weeks.
Longer studies may face data problems
When the researchers focused only on statistically significant results showing a benefit for medication, longer trials showed smaller effect sizes than studies lasting 12 weeks or less. The authors said that may reflect issues that become more likely as studies run longer, including participants dropping out or taking medication inconsistently.
Those problems can make results harder to interpret, particularly in studies involving people who may not be benefiting from the medication being tested. The authors said participants in shorter trials may be able to move sooner to effective treatment options if the test drug is not helping them.
The study does not say that longer trials have no value. It says shorter trials produced equivalent results in the body of research reviewed and, in some analyses, appeared to provide more dependable estimates of medication effects.
The authors recommended that future regulatory guidance and trial design weigh the evidence that shorter studies can detect medication effects for alcohol use disorder. They also pointed to practical advantages: shorter trials cost less and require less time from participants.
This story draws on original reporting from Medical Xpress.